Episode 4 of Supply Chain Signal examines PhRMA’s legal challenge to CMS’ GLOBE model and whether manufacturers can lower costs, expand U.S. production and strengthen supply chain resilience all at once.
News|Videos|September 24, 2026
Supply Chain Signal: How Policy Pressures Are Converging on Pharma
Author(s)Thani Jambulingam, PhD, Stephen Appezzato
Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.
Advertisement
Advertisement
The third episode of Supply Chain Signal, featuring pharmaceutical supply chain expert Thanigavelan Jambulingam, Ph.D., of Saint Joseph's University's Haub School of Business, looks at the latest expansion of most favored nation (MFN) pricing, the GENEROUS Model, and examines whether Medicare negotiation, international reference pricing and tariffs, taken together, are changing how drugs are priced, made and brought to market.
Related to this article
A CMS final rule codifies Medicare drug price negotiation from 2029, adds a fixed combination drug policy and implements a small biotech price floor.
Foreign-trade zones allow pharma companies to hold imported inventory closer to U.S. demand while deferring duties and keeping market allocation open.
The rule targets PBMs, but rebate, price protection and formulary deals they strike with drugmakers will be disclosed to plan fiduciaries and open to audit.
DOL's final rule requires PBMs to disclose rebates and formulary incentives to large self-insured plans for plan years beginning on or after July 1, 2027.
In this week’s Pharma Pulse, GoodRx expands an employer offering built on manufacturer pricing for GLP-1 obesity drugs, a federal judge declines to block Lilly’s comparative Zepbound ads, and the PBM industry’s trade group turns the vertical integration debate toward drug wholesalers.
Why outdated paper prescribing information is creating unnecessary cost, complexity and friction across a modern pharmaceutical supply chain.
At LogiPharma USA 2026, Mark Talens explains how end-to-end visibility lets pharma see its value chain across functions, and where supply chain monitoring is headed next.
Advertisement
Advertisement